

# James M Hoffman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3652978/publications.pdf>

Version: 2024-02-01

87  
papers

4,995  
citations

117625

34  
h-index

95266

68  
g-index

87  
all docs

87  
docs citations

87  
times ranked

4942  
citing authors

#	ARTICLE	IF	CITATIONS
1	Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 89-106.	9.4	442
2	Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). <i>Genetics in Medicine</i> , 2017, 19, 215-223.	2.4	410
3	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. <i>Current Drug Metabolism</i> , 2014, 15, 209-217.	1.2	341
4	PG4KDS: A model for the clinical implementation of preemptive pharmacogenetics. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2014, 166, 45-55.	1.6	221
5	The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 171-175.	4.7	207
6	Development and use of active clinical decision support for preemptive pharmacogenomics. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, e93-e99.	4.4	186
7	The Second Victim Experience and Support Tool: Validation of an Organizational Resource for Assessing Second Victim Effects and the Quality of Support Resources. <i>Journal of Patient Safety</i> , 2017, 13, 93-102.	1.7	159
8	Economic Evaluations of Clinical Pharmacy Services: 2006-2010. <i>Pharmacotherapy</i> , 2014, 34, 771-793.	2.6	148
9	Intravenous Zanamivir for Oseltamivir-Resistant 2009 H1N1 Influenza. <i>New England Journal of Medicine</i> , 2010, 362, 88-89.	27.0	128
10	Development and implementation of a pharmacist-managed clinical pharmacogenetics service. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 143-150.	1.0	128
11	Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 Update. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 499-500.	4.7	123
12	NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, S-1-S-22.	4.9	118
13	Integrating pharmacogenomics into electronic health records with clinical decision support. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1967-1976.	1.0	118
14	A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 563-566.	4.7	94
15	National survey on the effect of oncology drug shortages on cancer care. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 609-617.	1.0	90
16	Patient Safety Culture and the Second Victim Phenomenon: Connecting Culture to Staff Distress in Nurses. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2016, 42, 377-AP2.	0.7	89
17	The Effects of the Second Victim Phenomenon on Work-Related Outcomes: Connecting Self-Reported Caregiver Distress to Turnover Intentions and Absenteeism. <i>Journal of Patient Safety</i> , 2021, 17, 195-199.	1.7	87
18	Economic Evaluations of Clinical Pharmacy Services: 2001-2005. <i>Pharmacotherapy</i> , 2009, 29, 128-128.	2.6	84

#	ARTICLE	IF	CITATIONS
19	Medication Errors Caused by Confusion of Drug Names. Drug Safety, 2003, 26, 445-452.	3.2	83
20	Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 796-801.	4.4	83
21	Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. JAMA - Journal of the American Medical Association, 2021, 325, 2500.	7.4	83
22	Evidence and resources to implement pharmacogenetic knowledge for precision medicine. American Journal of Health-System Pharmacy, 2016, 73, 1977-1985.	1.0	79
23	ASHP Guidelines on Preventing Medication Errors with Chemotherapy and Biotherapy. American Journal of Health-System Pharmacy, 2015, 72, e6-e35.	1.0	72
24	Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. Pediatrics, 2016, 138, .	2.1	71
25	National trends in prescription drug expenditures and projections for 2014. American Journal of Health-System Pharmacy, 2014, 71, 482-499.	1.0	62
26	Projecting future drug expendituresâ€”2012. American Journal of Health-System Pharmacy, 2012, 69, 405-421.	1.0	59
27	Pharmacogenomics competencies in pharmacy practice: A blueprint for change. Journal of the American Pharmacists Association: JAPhA, 2017, 57, 120-125.	1.5	58
28	Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genetics in Medicine, 2019, 21, 1224-1232.	2.4	57
29	Biosimilars: Implications for health-system pharmacists. American Journal of Health-System Pharmacy, 2013, 70, 2004-2017.	1.0	54
30	Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. Pharmacogenomics, 2018, 19, 847-860.	1.3	53
31	Posaconazole Therapeutic Drug Monitoring in Pediatric Patients and Young Adults with Cancer. Annals of Pharmacotherapy, 2013, 47, 976-983.	1.9	50
32	Expanding evidence leads to new pharmacogenomics payer coverage. Genetics in Medicine, 2021, 23, 830-832.	2.4	49
33	ASHP Statement on the Pharmacistâ€™s Role in Clinical Pharmacogenomics. American Journal of Health-System Pharmacy, 2022, 79, 704-707.	1.0	37
34	Projecting future drug expendituresâ€”2009. American Journal of Health-System Pharmacy, 2009, 66, 237-257.	1.0	36
35	Projecting future drug expendituresâ€”2011. American Journal of Health-System Pharmacy, 2011, 68, 921-932.	1.0	34
36	National trends in prescription drug expenditures and projections for 2020. American Journal of Health-System Pharmacy, 2020, 77, 1213-1230.	1.0	34

#	ARTICLE	IF	CITATIONS
37	Priorities for Pediatric Patient Safety Research. <i>Pediatrics</i> , 2019, 143, .	2.1	33
38	Projecting future drug expendituresâ€™2005. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, 149-167.	1.0	32
39	Projecting future drug expendituresâ€™2008. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 234-253.	1.0	32
40	Improving Patient Handoffs and Transitions through Adaptation and Implementation of I-PASS Across Multiple Handoff Settings. <i>Pediatric Quality &amp; Safety</i> , 2020, 5, e323.	0.8	32
41	National trends in prescription drug expenditures and projections for 2021. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 1294-1308.	1.0	32
42	Adverse Drug Event Detection in Pediatric Oncology and Hematology Patients: Using Medication Triggers to Identify Patientâ€™Harm in a Specialized Pediatric Patient Population. <i>Journal of Pediatrics</i> , 2014, 165, 447-452.e4.	1.8	30
43	Alert dwell time: introduction of a measure to evaluate interruptive clinical decision support alerts. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, e138-e141.	4.4	30
44	National trends in prescription drug expenditures and projections for 2019. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 1105-1121.	1.0	29
45	ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 84-112.	1.0	29
46	Projecting future drug expendituresâ€™2007. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 298-314.	1.0	27
47	Projecting future drug expendituresâ€™2004. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 145-158.	1.0	26
48	Projecting future drug expendituresâ€™2006. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 123-138.	1.0	26
49	Safe and Successful Implementation of CPOE for Chemotherapy at a Children's Cancer Center. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, S-36-S-50.	4.9	26
50	Projecting future drug expendituresâ€™2003. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 137-149.	1.0	25
51	Validation of the Second Victim Experience and Support Tool-Revised in the Neonatal Intensive Care Unit. <i>Journal of Patient Safety</i> , 2021, 17, 531-540.	1.7	22
52	National trends in prescription drug expenditures and projections for 2022. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1158-1172.	1.0	22
53	Pharmacists Leading the Way to Precision Medicine: Updates to the Core Pharmacist Competencies in Genomics. <i>American Journal of Pharmaceutical Education</i> , 2022, 86, 8634.	2.1	21
54	Projecting future drug expendituresâ€™2010. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 919-928.	1.0	19

#	ARTICLE	IF	CITATIONS
55	Projecting future drug expenditures in U.S. nonfederal hospitals and clinics—2013. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 525-539.	1.0	19
56	ASHP Foundation Pharmacy Forecast 2018: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 23-54.	1.0	19
57	Pharmacy residency training in academic medical centers. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 2528-2533.	1.0	18
58	NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for Stakeholders. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, S-7-S-27.	4.9	18
59	Efficacy and Safety of Cefepime in Pediatric Patients: A Systematic Review and Meta-Analysis. <i>Journal of Pediatrics</i> , 2010, 157, 490-495.e1.	1.8	17
60	Preemptively Precise: Returning and Updating Pharmacogenetic Test Results to Realize the Benefits of Preemptive Testing. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 942-944.	4.7	17
61	Advancing Pharmacogenomics from Single-Gene to Preemptive Testing. <i>Annual Review of Genomics and Human Genetics</i> , 2022, 23, 449-473.	6.2	15
62	Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 409-415.	1.0	14
63	Optimizing Drug-Drug Interaction Alerts Using a Multidimensional Approach. <i>Pediatrics</i> , 2019, 143, .	2.1	14
64	ASHP Foundation Pharmacy Forecast 2019: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 71-100.	1.0	14
65	ASHP Foundation Pharmacy Forecast 2021: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 472-497.	1.0	12
66	Accelerating Improvement in Children's Healthcare Through Quality Improvement Collaboratives: a Synthesis of Recent Efforts. <i>Current Treatment Options in Pediatrics</i> , 2019, 5, 111-130.	0.6	11
67	Risk evaluation and mitigation strategies: Challenges and opportunities for health-system pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 1547-1554.	1.0	10
68	ASHP Foundation Pharmacy Forecast 2017: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 27-53.	1.0	10
69	Biomedical Data Science and Informatics Challenges to Implementing Pharmacogenomics with Electronic Health Records. <i>Annual Review of Biomedical Data Science</i> , 2020, 3, 289-314.	6.5	10
70	Developing Evidence for New Patient Safety Bundles Through Multihospital Collaboration. <i>Journal of Patient Safety</i> , 2019, Publish Ahead of Print, e1576-e1584.	1.7	8
71	The safety of cefepime and ceftazidime in pediatric oncology patients. <i>Pediatric Blood and Cancer</i> , 2013, 60, 806-809.	1.5	7
72	Implications of the FDA Draft Guidance on Biosimilars for Clinicians: What We Know and Don't Know. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 368-372.	4.9	5

#	ARTICLE	IF	CITATIONS
73	Using EHR Data to Detect Prescribing Errors in Rapidly Discontinued Medication Orders. <i>Applied Clinical Informatics</i> , 2018, 09, 082-088.	1.7	5
74	Associations of job demands and patient safety event involvement on burnout among a multidisciplinary group of pediatric hematology/oncology clinicians. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29214.	1.5	5
75	The genomic CDS sandbox: An assessment among domain experts. <i>Journal of Biomedical Informatics</i> , 2016, 60, 84-94.	4.3	4
76	Never Enough Time: Mixed Methods Study Identifies Drivers of Temporal Demand That Contribute to Burnout Among Physicians Who Care for Pediatric Hematology-Oncology Patients. <i>JCO Oncology Practice</i> , 2021, 17, e958-e971.	2.9	4
77	Transparent and reproducible reports of economic evaluations of clinical pharmacy services: A goal for the future?. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 442-443.	1.0	3
78	Accuracy of annual prescription drug expenditure forecasts in<i>AJHP</i>. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 1642-1648.	1.0	3
79	Approaches to assessing the provider experience with clinical pharmacogenomic information: a scoping review. <i>Genetics in Medicine</i> , 2021, 23, 1589-1603.	2.4	3
80	Why do subcutaneous ports get stuck? A case-control study. <i>Journal of Pediatric Surgery</i> , 2022, 57, 229-233.	1.6	3
81	An adaptive, asymptomatic SARS-CoV-2 workforce screening program providing real-time, actionable monitoring of the COVID-19 pandemic. <i>PLoS ONE</i> , 2022, 17, e0268237.	2.5	3
82	Preventing chemotherapy errors: Updating guidelines to meet new challenges. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 668-669.	1.0	2
83	Advancing pharmacogenomics into practice. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 603-604.	1.0	1
84	A nucleic acid amplification testâ€based strategy does not help inform return to work for healthcare workers with COVIDâ€19. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 851-853.	3.4	1
85	Patent expiration for lansoprazole. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 2253-2253.	1.0	0
86	Leveraging precision medicine to mitigate medication-safety challenges. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 2031-2032.	1.0	0
87	Quality improvement knowledge in pediatric hematology/oncology physicians: A need for improved education. <i>Pediatric Blood and Cancer</i> , 0, , .	1.5	0